Focus on head and neck cancer

Slides:



Advertisements
Similar presentations
34 Cancer.
Advertisements

Advanced Cancer Topics Journal Review 4/16/2009 AD.
1. Cancer and the cell cycle
Copyright © 2009 Pearson Education, Inc. Essentials of Genetics Seventh Edition Klug, Cummings, Spencer, Palladino Chapter 16 Cell Cycle Regulation and.
CANCER : Is a growth that happens because of uncontrolled cell division (mitosis) These changes are caused because of damage to genes in DNA. Cancer can.
Genetic testing for high-risk colon cancer patients1 William M. Grady Gastroenterology Volume 124, Issue 6, Pages (May 2003) DOI: /S (03)
Signal transduction. General scheme There are two general types of receptors: cell-surface and intracellular receptors.
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP  CHEST 
The Genetic Basis of Cancer
Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma  Fred C. Lam, Michael B. Yaffe  Cancer.
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.
Volume 16, Issue 3, Pages (July 2016)
Inhibitor of MAP kinase activation blocks colon cancer growth
Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Volume 100, Issue 1, Pages (January 2000)
HER2/HER3 heterodimers in prostate cancer
c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer
K. Lenhard Rudolph, Daniel Hartmann, Oliver G. Opitz  Gastroenterology 
Figure 4 Possible combination therapies CDK4/6 inhibitors
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Dan Gordon  Gastroenterology  Volume 114, Issue 4, (April 1998)
Colon Cancer Stem Cells: Promise of Targeted Therapy
Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.
Mariëlle I. Gallegos Ruiz, MSc, Hester van Cruijsen, MD, Egbert F
(A) An overview of the JAK/STAT signalling pathway.
Deconstructing ERK Signaling in Tumorigenesis
Volume 13, Issue 1, Pages 1-2 (January 2008)
Volume 29, Issue 3, Pages (March 2016)
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer  Vassiliki Papadimitrakopoulou,
A genome-based strategy uncovers frequent BRAF mutations in melanoma
Toru Furukawa  Clinical Gastroenterology and Hepatology 
Apoptosis-targeted therapies for cancer
A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin 
Volume 22, Issue 6, Pages (December 2012)
Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills  Cancer Cell 
The Thymus and the Immune System: Layered Levels of Control
Volume 3, Issue 4, Pages (April 2003)
Vascular Endothelial Growth Factor (VEGF) Pathway
The Hallmarks of Cancer
Characterizing the Killer Colorectal Carcinomas
Lung Cancer: A Wily Genetic Opponent
Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer  Thomas Winder, Heinz–Josef.
Oncogenes and Angiogenesis: Signaling Three-Dimensional Tumor Growth
Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench  Kenichi Suda, MD, PhD, Paul A. Bunn,
Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR
A Translational View of the Molecular Pathogenesis of Lung Cancer
Apoptosis-targeted therapies for cancer
Thymoma and Thymic Carcinoma: Molecular Pathology and Targeted Therapy
Normal cells (orange), often after long-term exposure to carcinogens, can obtain changes in key molecular pathways and cause uncontrolled proliferation.
Do Cancer Cells Care If Their Host Is Hungry?
Benjamin Solomon, MBBS, PhD, Richard B. Pearson, PhD 
In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)
Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas  Jun Fan, MD  Journal of Thoracic.
Smoothing Out Drug Resistance
Progress in Cutaneous Cancer Research1
Volume 69, Issue 11, Pages (June 2006)
Susan J. Clark, Peter L. Molloy  Cancer Cell 
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
A Missing Link in Genotype-Directed Cancer Therapy
History of Oncolytic Viruses: Genesis to Genetic Engineering
The new kid on the block(ade) of the IGF-1 receptor
Volume 1, Issue 3, Pages (April 2002)
Sticking It to Cancer with Molecular Glue for SHP2
Tyrosine kinase inhibitors
Novel therapies for chronic myelogenous leukemia
Volume 25, Issue 2, Pages (January 2007)
Is Cyclin D1-CDK4 kinase a bona fide cancer target?
Volume 3, Issue 4, Pages (April 2003)
Presentation transcript:

Focus on head and neck cancer Li Mao, Waun K Hong, Vassiliki A Papadimitrakopoulou  Cancer Cell  Volume 5, Issue 4, Pages 311-316 (April 2004) DOI: 10.1016/S1535-6108(04)00090-X

Figure 1 Multistep process and field effect in HNSCC tumorigenesis Chronic exposure to tobacco carcinogens in the upper aerodigestive tract causes genetic and epigenetic damage in epithelial cells. Accumulation of this damage leads to the development of premalignant lesions and invasive cancers. Understanding the common genetic and epigenetic alterations that are important in the tumorigenic process is critical in the development of molecularly based management strategies. Cancer Cell 2004 5, 311-316DOI: (10.1016/S1535-6108(04)00090-X)

Figure 2 Field cancerization versus clonal spread The diagram shows the sites of 14 oral lesions that developed in a patient over 10 years. There were nine invasive cancers and five premalignant lesions. Each lesion was treated by complete resection at the time of diagnosis. Each lesion is numbered according to the sequence of diagnosis. Lesions with the same color shared identical genetic alterations, suggesting the same clonal origin based on results of genetic analysis and a mathematic model. Four independent clones might have been responsible for the development of all 14 oral lesions in this patient. Cancer Cell 2004 5, 311-316DOI: (10.1016/S1535-6108(04)00090-X)

Figure 3 Simplified scheme of the molecular abnormalities within signal transduction pathways in HNSCC that are possible targets for intervention with targeted therapies C225, cetuximab; IGF, insulin-like growth factor; Abs, antibodies; RTKIs, receptor tyrosine kinase inhibitors; FTI, farnesyl transferase inhibitors; Cdk, cyclin-dependent kinase. Cancer Cell 2004 5, 311-316DOI: (10.1016/S1535-6108(04)00090-X)